Catalent Names Zoetis CFO Wetteny Joseph to Lead Pharma and Consumer Health Unit
Event summary
- Wetteny Joseph appointed Group President, Pharma and Consumer Health at Catalent, effective November 2, 2026.
- Joseph succeeds Aris Gennadios, who is leaving after a 24-year tenure at Catalent.
- Joseph previously served as EVP and CFO at Zoetis and held senior roles at Catalent, including SVP and CFO.
- He will report directly to CEO Alessandro Maselli and join Catalent’s Group Executive Committee.
The big picture
Catalent’s appointment of Wetteny Joseph reflects a strategic pivot to leverage his global leadership experience and financial acumen. His background in driving business growth and transformation at Zoetis suggests a focus on operational excellence and value creation. The move comes amid increasing competition in the CDMO space, where scale and strategic investments are critical for sustaining growth.
What we're watching
- Strategic Realignment
- How Joseph’s experience at Zoetis will influence Catalent’s PCH segment strategy.
- Execution Risk
- Whether Joseph can sustain the growth trajectory of the PCH business.
- Governance Dynamics
- The impact of Joseph’s appointment on Catalent’s Group Executive Committee dynamics.
Related topics
